- 询价
- Nebulabio
- 中国
- NBL-288270
- 2025年12月23日
企业认证
相关产品推荐更多 >
重组人CDCA7蛋白 | Recombinant Human CDCA7 Protein, 246-371aa, His-tag
询价
白蛋白 | Native Rat Albumin
询价重组人RMDN3蛋白 | Recombinant Human RMDN3 Protein, 231-470aa, His-tag
询价重组人TRIM33, TIF1-γ蛋白 | Recombinant Human TRIM33/TIF1-γ Protein, 882-1087aa, His-tag
询价
Recombinant Yersinia enterocolitica OsmY Protein, 27-204aa, His-tag
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保质期：
见COA
- 库存：
大量
- 供应商：
北京辰辉创聚生物技术有限公司
- 规格：
100ug; 500ug; 1mg; Bulk
| 产品信息
品名：NebuSelect™ Recombinant Canine GM-CSF
中文名称：重组Canine GM-CSF蛋白
别名：P48749, GM-CSF, CSF2
货号：NBL-288270
品牌：Nebulabio
规格：100UG；1MG；Bulk
| 产品描述
NebuSelect™ Recombinant Canine GM-CSF (CAT#NBL-288270) is expressed in E.coli. This recombinant protein is of high purity, verified to be greater than 95% by SDS-PAGE. Endotoxin levels are less than 1 EU/µg, as determined by the LAL (Limulus Amebocyte Lysate) assay. Please contact us freely to get bioactivity data.
| 产品属性
Species:Canine
Expression System:E.coli
Molecular Weight:14.2 kDa
Target Name:GM-CSF
Purity:＞95%
Formulation:See COA
Endotoxin:＜1 EU/ug(LAL Method)
Storage:4°C for short term. -20°C for long term.
For Research Use Only!
To get more information, please contact us freely.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Canine Adenovirus Downstream Processing Protocol
against the vectors. This preexisting immunity limits their clinical success. Strategies to circumvent this problem include the use of nonhuman adenovirus vectors. Vectors derived from canine adenovirus type 2 (CAV-2) are among the best-studied representatives. CAV
Synthesis of Recombinant Human Cytokine GM-CSF in the Seeds of Transgenic Tobacco Plants
We are interested in studying plant systems as vehicles for the production of recombinant proteins of clinical relevance. There are a number of potential advantages to producing recombinant protein products in plants. Plants are more economical
Acute myeloid leukemia (AML) has an annual incidence of 2.4 cases per 100,000 persons and is the most common form of acute leukemia in adults (1 , 2 ). AML is a model for drug-resistant human cancers, and current therapies for AML possess
技术资料暂无技术资料 索取技术资料
